1. 1. S. C. Chattoraj, N. B. Watts, and N. W. Trietz. Textbook of Clinical Chemistry, Saunders, Philadelphia, 1986, pp. 1116–1138.
2. 2. S. Refetoff, P. R. Larsen, L. J. DeGroot, G. M. Besser, G. F. Cahill, and E. Steinberger. Endocrinology, Vol. 1, 2nd ed., Saunders, Philadelphia, 1989, Ch. 38.
3. 3. S. Pannain, M. Feldman, U. Eiholzer, R. E. Weiss, N. H. Scherberg, and S. Refetoff. Familial dysalbuminemic hyperthyroxinemia in a swiss family caused by a mutant albumin (R218P) shows an apparent discrepancy between serum concentration and affinity for thyroxine. J. Clin. Endocrinol. Metab. 85:2786–2792 (2000).
4. 4. L. D. Mechtol and W. I. Warner. Dextrothyroxine for lowering serum cholesterol. Analysis of data on 6066 patients. Angiology 20:565–579 (1969).
5. 5. P. Starr. Depression of the serum cholesterol level in myxedematous patients by an oral dosage of sodium dextro-thyroxine which has no effct on the basal metabolic rate or electrocardiogram. J Clin Endocr. 20:116–119 (1960).